Cited by 211Neuropeptides and Animal PhysiologyNeuroendocrine regulation and behaviorStress Responses and Cortisol

The DOI matches its Crossref record; 243 of the 245 references it cites were found in a registry or an index.

Behavioral effects of neuropeptides in rodent models of depression and anxiety

Rotzinger, Susan, Lovejoy, David A., Tan, Laura A.·2010·Peptides

DOI 10.1016/j.peptides.2009.12.015

Open this paper in CoChat — free account

Abstract

In recent years, studies have advocated neuropeptide systems as modulators for the behavioral states found in mood disorders such as depression and anxiety disorders. Neuropeptides have been tested in traditional animal models and screening procedures that have been validated by known antidepressants and anxiolytics. However, it has become clear that although these tests are very useful, neuropeptides have distinct behavioral effects and dose-dependent characteristics, and therefore, use of these tests with neuropeptides must be done with an understanding of their unique characteristics. This review will focus on the behavioral actions of neuropeptides and their synthetic analogs, particularly in studies utilizing various preclinical tests of depression and anxiety. Specifically, the following neuropeptide systems will be reviewed: corticotropin-releasing factor (CRF), urocortin (Ucn), teneurin C-terminal associated peptide (TCAP), neuropeptide Y (NPY), arginine vasopressin (AVP), oxytocin, the Tyr-MIF-1 family, cholecystokinin (CCK), galanin, and substance P. These neuropeptide systems each have a unique role in the regulation of stress-like behavior, and therefore provide intriguing therapeutic targets for mood disorder treatment.

Integrity signals

Registry

Crossref · 10.1016/j.peptides.2009.12.015

Cites

243 of 243 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Items 201–243 of 243

MIF-I suppresses deprivation-induced fluid consumption in rats
Olson, R. D., Kastin, A. J., Olson, G. A., King, B. M., von Almen, T. K., Berzas, M. C., Ibanez, M. L., & Coy, D. H. (1980) · Peptides · doi:10.1016/0196-9781(80)90014-5 · Cited by 40
Repeated intracerebral teneurin C-terminal associated peptide (TCAP)-1 injections produce enduring changes in behavioral responses to corticotropin-releasing factor (CRF) in rat models of anxiety
Tan, L. A., Xu, K. H., Vaccarino, F. J., Lovejoy, D. A., & Rotzinger, S. (2007) · Behavioural Brain Research · doi:10.1016/j.bbr.2007.10.032 · Cited by 39
Self-citation
Teneurin carboxy (C)-terminal associated peptide-1 inhibits alkalosis-associated necrotic neuronal death by stimulating superoxide dismutase and catalase activity in immortalized mouse hypothalamic cells
Trubiani, G., Chawaf, A. A., Belsham, D. D., Baršytė-Lovejoy, D., & Lovejoy, D. A. (2007) · Brain Research · doi:10.1016/j.brainres.2007.07.087 · Cited by 39
Self-citation
Non-Monoamine-Based Approach for the Treatment of Depression and Anxiety Disorders
Chaki, S., Okubo, T., & Sekiguchi, Y. (2006) · Recent Patents on CNS Drug Discovery · doi:10.2174/157488906775245318 · Cited by 39
The substance P (NK1) receptor antagonist L-760735 inhibits fear conditioning in gerbils
Rupniak, N. M. J. (2003) · Neuropharmacology · doi:10.1016/s0028-3908(03)00023-6 · Cited by 38
MIF-1 is active in a chronic stress animal model of depression
Pignatiello, M. F., Olson, G. A., Kastin, A. J., Ehrensing, R. H., McLean, J. H., & Olson, R. D. (1989) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(89)90027-0 · Cited by 38
Benzodiazepine-induced amnesia in rats: Reinstatement of conditioned performance by noxious stimulation on test.
Harris, J. A., & Westbrook, R. F. (1998) · Behavioral Neuroscience · doi:10.1037/0735-7044.112.1.183 · Cited by 37
The reversal effect of antidepressants on the escape deficit induced by inescapable shock in rats
Kametani, H., Nomura, S., & Shimizu, J. (1983) · Psychopharmacology · doi:10.1007/bf00436153 · Cited by 36
The four-plates test: Anxiolytic or analgesic paradigm?
Ripoll, N., Hascoët, M., & Bourin, M. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2005.11.036 · Cited by 36
Design and Synthesis of Photoaffinity-Labeling Ligands of the l -Prolyl- l -leucylglycinamide Binding Site Involved in the Allosteric Modulation of the Dopamine Receptor
Fisher, A., Mann, A., Verma, V., Thomas, N., Mishra, R. K., & Johnson, R. L. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050644n · Cited by 35
Chronic stimulation of corticotropin-releasing factor receptor 1 enhances the anxiogenic response of the cholecystokinin system
Sherrin, T., Todorovic, C., Zeyda, T., Tan, C. H., Hon, P. W. T., Zhu, Y. Z., & Spiess, J. (2008) · Molecular Psychiatry · doi:10.1038/sj.mp.4002121 · Cited by 35
Corticotropin-Releasing Hormone1 Receptors Mediate Consensus Interferon-α YM643-Induced Depression-Like Behavior in Mice
Yamano, M., Yuki, H., Yasuda, S., & Miyata, K. (2000) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35275-9 · Cited by 34
Behavioral and neuroendocrine actions of endomorphin-2
Bujdosó, E., Jászberényi, M., Tömböly, C., Tóth, G., & Telegdy, G. (2001) · Peptides · doi:10.1016/s0196-9781(01)00466-1 · Cited by 33
The CCKB antagonist, L-365,260, attenuates fear-potentiated startle
Josselyn, S. A., Frankland, P. W., Petrisano, S., Bush, D. E. A., Yeomans, J. S., & Vaccarino, F. J. (1995) · Peptides · doi:10.1016/0196-9781(95)02013-m · Cited by 32
Multiple interaction sites of galnon trigger its biological effects
Florén, A., Sollenberg, U. E., Lundström, L., Zorko, M., Stojan, J., Budihna, M. V., Wheatley, M., Martin, N. P., Kilk, K., Mazarati, A. M., et al. (2005) · Neuropeptides · doi:10.1016/j.npep.2005.09.005 · Cited by 32
Can Anti-Panic Drugs Antagonise the Anxiety Produced in the Rat by Drugs Acting at the GABA-Benzodiazepine Receptor Complex?
Pellow, S., & File, S. E. (2008) · Neuropsychobiology · doi:10.1159/000118341 · Cited by 30
Cellular and behavioural profile of the novel, selective neurokinin1 receptor antagonist, vestipitant: A comparison to other agents
Brocco, M., Dekeyne, A., la Cour, C. M., Touzard, M., Girardon, S., Veiga, S., Nanteuil, G. D., A, T. R. D. J., Olivier, B., & Millan, M. J. (2008) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2008.06.002 · Cited by 30
Effect of imipramine in the “learned helplessness” model of depression in rats is not mimicked by combinations of specific reuptake inhibitors and scopolamine
Geoffroy, M., Scheel‐Krüger, J., & Christensen, A. V. (1990) · Psychopharmacology · doi:10.1007/bf02244056 · Cited by 28
Anxiolytic-like effects of substance P administration into the dorsal, but not ventral, hippocampus and its influence on serotonin
de Carvalho, M. C., Masson, S., Brandão, M. L., & Silva, M. A. D. S. (2008) · Peptides · doi:10.1016/j.peptides.2008.02.014 · Cited by 27
Psychotropic properties of oxytocin
Vd, B., Sm, T., & Lozhkina, T. K. (1986) · Neuroscience and Behavioral Physiology · doi:10.1007/bf01186517 · Cited by 27
Further evidence on the anxiogenic-like effect of substance P evaluated in the elevated plus-maze in rats
Duarte, F. S., Testolin, R., & de Lima, T. C. M. (2004) · Behavioural Brain Research · doi:10.1016/j.bbr.2004.03.020 · Cited by 26
Effects of Endomorphin-1 on Open-Field Behavior and on the Hypothalamic-Pituitary-Adrenal System
Bujdosó, E., Jászberényi, M., Tömböly, C., Tóth, G., & Telegdy, G. (2001) · Endocrine · doi:10.1385/endo:14:2:221 · Cited by 23
Administration of the galanin antagonist M40 into lateral septum attenuates shock probe defensive burying behavior in rats
Echevarria, D. J., Hernandez, A., Diogenes, A. R., & Morilak, D. A. (2005) · Neuropeptides · doi:10.1016/j.npep.2005.06.004 · Cited by 22
Antidepressant-like effects of a novel pentapeptide, nemifitide, in an animal model of depression
Overstreet, D. H., Hlavka, J., Feighner, J. P., Nicolau, G., & Freed, J. S. (2004) · Psychopharmacology · doi:10.1007/s00213-004-1815-9 · Cited by 20
A double-blind, placebo-controlled, efficacy, safety, and pharmacokinetic study of INN 00835, a novel antidepressant peptide, in the treatment of major depression
Feighner, J. P., Ehrensing, R. H., Kastin, A. J., Leonard, B. E., Sverdlov, L., Nicolau, G., Patel, A., Hlavka, J., Abajian, H. B., & Noble, J. F. (2000) · Journal of Affective Disorders · doi:10.1016/s0165-0327(99)00187-1 · Cited by 20
Assessment of antidepressant and anxiolytic properties of NK1 antagonists and Substance P in Wistar Kyoto rats
Malkesman, O., Braw, Y., & Weller, A. (2007) · Physiology & Behavior · doi:10.1016/j.physbeh.2006.11.014 · Cited by 20
Double-blind, placebo-controlled study of INN 00835 (netamiftide) in the treatment of outpatients with major depression
Feighner, J. P., Ehrensing, R. H., Kastin, A. J., Patel, A., Sverdlov, L., Hlavka, J., Abajian, H. B., Noble, J. F., & Nicolau, G. (2001) · International Clinical Psychopharmacology · doi:10.1097/00004850-200111000-00005 · Cited by 18
Blockade of brain dopamine receptors antagonizes the anti-immobility effect of MIF-1 and Tyr-MIF-1 in rats
Pulvirenti, L., & Kastin, A. J. (1988) · European Journal of Pharmacology · doi:10.1016/0014-2999(88)90810-2 · Cited by 18
MIF-1 potentiates the action of tricyclic antidepressants in an animal model of depression
Kostowski, W., Danysz, W., Dyr, W., Jankowska, E. A., Krazaścik, P., Paklejko, W., Stefański, R., & Pklaźnik, A. (1991) · Peptides · doi:10.1016/0196-9781(91)90037-p · Cited by 15
Can CRF1receptor antagonists become antidepressant and/or anxiolytic agents?
Overstreet, D. H., Knapp, D. J., & Breese, G. R. (2005) · Drug Development Research · doi:10.1002/ddr.20023 · Cited by 14
The effect of drugs acting on CCK receptors and rat free exploration in the exploration box.
Matto, V., Harro, J., & Allikmets, L. (1997) · PubMed · Cited by 13
Efficacy and safety of 30 mg/d and 45 mg/d nemifitide compared to placebo in major depressive disorder
Montgomery, S., Feighner, J. P., Sverdlov, L., Shrivastava, R. K., Cunningham, L. A., Kiev, A., Hlavka, J., & Tonelli, G. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145705006139 · Cited by 13
Involvement of tachykinin NK1 receptor in the behavioral and immunological responses to swimming stress in mice
Teixeira, R. M., & de Lima, T. C. M. (2003) · Neuropeptides · doi:10.1016/j.npep.2003.08.002 · Cited by 13
Behavioral and immunological effects of substance P in female and male mice
TEIXEIRA, R. (2004) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2004.04.032 · Cited by 12
Influence of protease inhibitors on the antidepressant activity of oxytocin
Arletti, R., & Bertolini, A. (1987) · Neuropeptides · doi:10.1016/0143-4179(87)90074-6 · Cited by 11
Effect of Tyr‐MIF‐1 peptides on blood ACTH and corticosterone concentration induced by three experimental models of stress
Bocheva, A. I., Dzambazova, E., Tafradjiiska-Hadjiolova, R. K., Traikov, L. L., Mincheva, R. K., & Bivolarski, I. (2008) · Autonomic and Autacoid Pharmacology · doi:10.1111/j.1474-8673.2008.00425.x · Cited by 11
Rapid antidepressant activity of melanocyte-inhibiting factor: a clinical trial.
Levy, M. I., DeNigris, Y., & Kl, D. (1982) · PubMed · Cited by 11
Clinical effectiveness of nemifitide, a novel pentapeptide antidepressant, in depressed outpatients: comparison of follow-up re-treatment with initial treatment
Feighner, J. P., Sverdlov, L., Nicolau, G., Abajian, H. B., Hlavka, J., Freed, J. S., & Tonelli, G. (2003) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145703003481 · Cited by 9
The role of the neuropeptide galanin in forming type-specific behavioral characteristics
Lyudyno, V. I., Abdurasulova, I. N., & Клименко, В. М. (2007) · Neuroscience and Behavioral Physiology · doi:10.1007/s11055-008-0013-3 · Cited by 7
MIF-1 facilitates passive avoidance retention.
Puciłowski, O., Płaźnik, A., & Kostowski, W. (1982) · PubMed · Cited by 7
Effects of Tyr-MIF-1 on Stress-Induced Analgesia and the Blockade of Development of Morphine Tolerance by Stress in Mice
Hiroko, F., Takahashi, M., KANETO, H., & Masaaki, Y. (1999) · The Japanese Journal of Pharmacology · doi:10.1254/jjp.79.231 · Cited by 6
Comparison of systemic exposure to nemifitide following two methods of subcutaneous administration to healthy volunteers
Nicolau, G., Feighner, J. P., Stout, R., Hlavka, J., Gutierrez, M. M., Ciric, S., & Freed, J. (2005) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.470 · Cited by 5
Distribution of mRNAs encoding CRF receptors in brain and pituitary of rat and mouse
Van Pett, K., Viau, V., Bittencourt, J. C., Chan, R. K. W., Li, H.-Y., Arias, C., Prins, G. S., Perrin, M., Vale, W., & Sawchenko, P. E. (2000) · The Journal of Comparative Neurology · doi:10.1002/1096-9861(20001211)428:2

Flagged first, then by citations

2 of the 245 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

Deak, 1999, The impact of the nonpeptide corticotropin-releasing hormone antagonist antalarmin on behavioral and endocrine responses to stress, Endocrinology, 140, 79, 10.1210/en.140.1.79 · DOI · Paper page

Sorted by citations

The Effects of Psychological Stress on Depression
Yang, L., Zhao, Y., Wang, Y., Liu, L., Zhang, X., Li, B., & Cui, R. (2015) · Current Neuropharmacology · doi:10.2174/1570159x1304150831150507 · Cited by 589
Breaking the loop: Oxytocin as a potential treatment for drug addiction
McGregor, I. S., & Bowen, M. T. (2012) · Hormones and Behavior · doi:10.1016/j.yhbeh.2011.12.001 · Cited by 268
The Role of Oxytocin in Psychiatric Disorders: A Review of Biological and Therapeutic Research Findings
Cochran, D. M., Fallon, D., Hill, M., & Frazier, J. A. (2013) · Harvard Review of Psychiatry · doi:10.1097/hrp.0b013e3182a75b7d · Cited by 267
Stress, Endocrine Physiology and Pathophysiology -- Endotext
DeGroot, L. J., Chrousos, G. P., Dungan, K., Grossman, A. B., Jm, H., Koch, C., Korbonits, M., McLachlan, R., New, M., Purnell, J. Q., et al. (2000) · Europe PMC (PubMed Central) · Cited by 260
Comparative Analyses of Zebrafish Anxiety-Like Behavior Using Conflict-Based Novelty Tests
Kysil, E. V., Мешалкина, Д. А., Frick, E. E., Echevarria, D. J., Rosemberg, D. B., Maximino, C., Lima, M. G., de Abreu, M. S., Giacomini, A. C. V. V., Barcellos, L. J. G., et al. (2017) · Zebrafish · doi:10.1089/zeb.2016.1415 · Cited by 277

See all 211

Authors: Rotzinger, S., Lovejoy, D. A., & Tan, L. A.
Affiliations: University of Toronto (CA)
Corresponding author: Tan, Laura A.
ORCID: Rotzinger, Susan
Lovejoy, David A.
Venue: Peptides
Publisher: Elsevier BV
Published: 2010-04
Volume: 31
Issue: 4
Pages: 736-756
ISSN: 0196-9781 (ISSN-L)
DOI: 10.1016/j.peptides.2009.12.015
OpenAlex: W2087834131
Cited by: 211
References: 245
Citations by year: 2026: 3 · 2025: 6 · 2024: 8 · 2023: 5 · 2022: 10 · 2021: 6 · 2020: 6 · 2019: 8 · 2018: 9 · 2017: 14 · 2016: 10 · 2015: 12 · 2014: 21 · 2013: 24 · 2012: 27
FWCI: 1.97
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Peptides (publishedVersion)
PubMed (publishedVersion)
Funders: Canadian Institutes of Health Research (FRN 72027622)
Topics: Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Neuroendocrine regulation and behavior
Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
Keywords: neuropeptides, depression, anxiety, mood disorders, corticotropin-releasing factor, urocortin, neuropeptide Y, vasopressin, oxytocin, cholecystokinin, galanin, substance P, antidepressant screening, rodent models, therapeutic target
MeSH terms: Animals, Anxiety, Arginine Vasopressin, Behavior, Animal, Cholecystokinin, Corticotropin-Releasing Hormone, Depression, Disease Models, Animal, Humans, MSH Release-Inhibiting Hormone, Neuropeptide Y, Neuropeptides, Neuropsychological Tests, Oxytocin, Social Behavior, Galanin, Urocortins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Behavioral effects of neuropeptides in rodent models of depression and anxiety

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks